Pharmaceutical evidence workflows have evolved from spreadsheets and rule-based tools to NLP systems and generative AI copilots. Now, a new shift is emerging: the operator era, where AI can plan and execute multi-step workflows, use specialized tools, and present completed work for expert review.
At CapeStart, we help pharmaceutical and life sciences organizations move beyond task-level AI assistance by designing reliable, operator-model AI systems for regulated evidence workflows. Combining domain expertise, enterprise AI engineering, traceable architecture, and human-in-charge governance, we help organizations improve efficiency while maintaining transparency, quality, and expert oversight.
This white paper examines how operator-model AI is transforming systematic literature reviews, using risk-of-bias appraisal as a practical example. It explores the evolution from copilots to AI operators, the technical architecture required, current research findings, implementation considerations, limitations, and the role of human verification in judgment-intensive workflows.
Download the white paper to learn how your organization can adopt operator-model AI responsibly, accelerate evidence workflows, and build a scalable, auditable foundation for the next generation of pharmaceutical operations.
